Kali Therapeutics

Kali Therapeutics Achieves Disruptive Immune System Reset and Regeneration with T Cell Engagers Featuring Precise Targeting and Controllable Cytotoxicity. KT501 is a Novel IgG-like Trispecific T Cell Engager Designed for High-Affinity Binding to CD3, CD19, and BCMA, Enabling Targeting of a Broad Range of B Cell Populations. In December 2025, Kali Therapeutics Initiated the First-in-Human Study of KT501 in Rheumatoid Arthritis (RA) and Plans to Expand KT501 into Multiple Autoimmune Indications.